IGC Pharma, Inc. Income Statement
IGC|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
IGC Pharma, Inc. reported $1M in revenue and $7M in net loss for FY2025. Revenue has declined at a 8.0% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $911.0K | $397.0K | $898.0K | $4.1M | $5.1M | $2.2M | $580.4K | $6.4M | $7.7M | $2.3M | $8.0M | $4.2M | $4.2M | $4.1M |
| Cost of Revenue | $652.0K | $469.0K | $203.0K | $785.0K | $4.0M | $5.0M | $2.1M | $362.1K | $5.5M | $7.1M | $1.9M | $6.5M | $4.8M | $4.8M | $3.9M |
| Gross Profit | $619.0K | $442.0K | $194.0K | $113.0K | $115.0K | $132.0K | $82.0K | $218.2K | - | - | - | - | - | - | - |
| SG&A Expense | $4.4M | $8.6M | $13.3M | $7.9M | $6.0M | $3.5M | $1.7M | $2.3M | $2.7M | $4.1M | $2.2M | $3.0M | $4.7M | $4.7M | $7.3M |
| R&D Expense | $3.7M | $3.5M | $2.3M | $929.0K | $1.0M | $1.3M | $137.0K | - | - | - | - | - | - | - | - |
| Operating Income | -$7.4M | -$11.6M | -$15.4M | -$8.7M | -$6.9M | -$4.6M | -$1.8M | -$2.1M | -$2.9M | -$4.3M | -$2.5M | -$2.5M | -$7.5M | -$7.5M | -$15.9M |
| Interest Expense | - | $5.0K | $5.0K | $5.0K | $3.0K | - | - | $223.5K | $213.9K | $286.3K | $291.5K | $419.4K | $984.0K | $984.0K | $1.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $2.0K | $0 | $14.4K | $579 | $5.2K | $0 | -$365.1K | $172.8K | $172.8K | $4.1M |
| Net Income | -$7.1M | -$11.5M | -$15.0M | -$8.8M | -$7.3M | -$4.1M | -$1.8M | -$1.9M | -$2.8M | -$4.6M | -$3.0M | -$2.3M | -$7.8M | -$7.8M | -$20.2M |
| EPS (Basic) | -$0.22 | - | - | - | - | - | - | - | -$0.17 | -$0.31 | -$0.37 | -$0.32 | -$2.66 | -$2.66 | -$1.34 |
| EPS (Diluted) | -$0.22 | - | - | - | -$0.19 | -$0.13 | -$0.06 | -$0.07 | -$0.17 | -$0.31 | -$0.37 | -$0.32 | -$2.66 | -$2.66 | -$1.34 |
| Shares Outstanding | 80.9M | 53.1M | 51.1M | 47.8M | 39.3M | 39.5M | 30.8M | 28.3M | 23.3M | 1.3M | 1.3M | 1.3M | 13.0M | 6.0M | 14.9M |
| Gross Margin | 48.7% | 48.5% | 48.9% | 12.6% | 2.8% | 2.6% | 3.7% | 37.6% | - | - | - | - | - | - | - |
| Operating Margin | -585.8% | -1270.1% | -3886.2% | -971.5% | -168.6% | -90.8% | -81.6% | -354.0% | -45.6% | -56.5% | -111.2% | -30.9% | -178.9% | -178.9% | -390.0% |
| Profit Margin | -560.4% | -1263.0% | -3782.4% | -981.2% | -179.6% | -80.1% | -81.4% | -321.7% | -44.1% | -60.1% | -133.0% | -28.1% | -184.6% | -184.6% | -496.8% |